Latest Conference Articles

CDK4/6 Inhibitors Continue to Build Traction in Early-Stage ER+/HER2- Breast Cancer

July 30th 2021, 10:16pm

International Congress on the Future of Breast Cancer West

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.

Bispecifics Prove to Have Intriguing Role in Lung Cancer

July 30th 2021, 9:38pm

International Lung Cancer Congress

Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

Dr. Padda on Selecting a Therapy Following Osimertinib Resistance in NSCLC

July 30th 2021, 7:57pm

International Lung Cancer Congress

Sukhmani K. Padda, MD, discusses treatment selection following osimertinib resistance in patients with non–small cell lung cancer.

Optimizing Osimertinib Treatment Strategies Relies on Identification of Resistance

July 30th 2021, 6:40pm

International Lung Cancer Congress

Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor osimertinib in the first line setting are the key to unlocking the next wave of success in treating lung cancer.

Dr. Patel on the Potential With PARP/Immunotherapy Combos in NSCLC

July 30th 2021, 6:30pm

International Lung Cancer Congress

Sandip P. Patel, MD, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer.

New Strategies for RET Inhibition May Expand Their Role in NSCLC

July 30th 2021, 5:13pm

International Lung Cancer Congress

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

Understanding the Role of the Pulmonologist in the Diagnosis and Management of Lung Cancer

July 29th 2021, 9:41pm

International Lung Cancer Congress

Harmeet S. Bedi, MD, discusses the important role of pulmonologists in the diagnosis and management of patients with lung cancer.

MRD Offers a Potential Predictive Strategy to Further Personalize Treatment in NSCLC

July 29th 2021, 9:00pm

International Lung Cancer Congress

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Pal Provides Perspective on Pivotal Trials in RCC and Prostate Cancer

July 27th 2021, 5:00pm

ASCO Direct Highlights

Insights generated from several trials presented during the 2021 ASCO Annual Meeting in renal cell carcinoma illustrate the importance of evaluating checkpoint inhibitors in earlier stages of disease, quality of life, and long-term outcomes, and other data that point to 2 potential new standards of care in prostate cancer.

Siddiqi Spotlights Latest Data on Optimization of Therapy in Hematologic Malignancies

July 23rd 2021, 1:00pm

ASCO Direct Highlights

Data presented during the 2021 ASCO Annual Meeting offered insight into the optimization of BTK inhibitors, induction therapy, consolidative therapy, and radiation therapy for patients across the paradigm of hematologic malignancies.

Novel Vaccine Combos Represent a Promising Treatment Approach in Breast Cancer

July 19th 2021, 8:40pm

International Congress on the Future of Breast Cancer East

The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.

Dr. Tolaney on Tailoring HER2-Directed Therapy in Breast Cancer

July 19th 2021, 8:22pm

International Congress on the Future of Breast Cancer East

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer. 

SERDs Represent the Next Generation of ER-Targeting Therapy in Breast Cancer

July 19th 2021, 7:28pm

International Congress on the Future of Breast Cancer East

Selective estrogen receptor degraders are becoming increasingly important in the treatment of ER-positive metastatic breast cancer.

Chemoimmunotherapy Shakes Up Metastatic and Early-Stage TNBC

July 17th 2021, 10:00am

International Congress on the Future of Breast Cancer East

Chemoimmunotherapy combinations have transformed the treatment landscape for patients with triple-negative breast cancer, but balancing potential efficacy with the risk of toxicity with these regimens is critical in both the metastatic and early-stage settings.

Tolaney Spotlights Tailoring Therapy by Risk in HER2+ Breast Cancer

July 16th 2021, 8:15pm

International Congress on the Future of Breast Cancer East

By adapting adjuvant therapy based on responses to preoperative therapy, investigators may be able to change long term outcomes for patients with HER2-positive breast cancer, creating a paradigm shift in the space.

Dr. Wagaskar on Potential Explanations for the Obesity Paradox in Prostate Cancer

July 12th 2021, 9:01pm

European Association of Urology Congress

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.

Dr. Sereti on the Next Steps for NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

July 12th 2021, 8:57pm

European Association of Urology Congress

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.

Darolutamide Demonstrates Favorable Tolerability in Nonmetastatic CRPC

July 12th 2021, 6:50pm

European Association of Urology Congress

Treatment with darolutamide induced a low cumulative incidence of hormone treatment–related adverse effects that was comparable to treatment with placebo in patients with nonmetastatic castration-resistant prostate cancer, according to findings from a safety analysis of the phase 3 ARAMIS trial.

Neoadjuvant Apalutamide Does Not Interfere With Robotic Prostatectomy

July 12th 2021, 5:52pm

European Association of Urology Congress

Intense androgen receptor inhibition with neoadjuvant apalutamide did not complicate robotic prostatectomy surgical outcomes.

Patients With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10th 2021, 4:55pm

European Association of Urology Congress

Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those without the virus.